Genetron Holdings Limited ("Genetron Health" or the "Company",
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today reported its unaudited financial results for the second
quarter ended June 30, 2022.
Recent Business Highlights
- Received College of American
Pathologists (CAP) Accreditation for its laboratory in
Maryland.
- Presented 27 new research abstracts
at the 2022 American Society of Clinical Oncology (ASCO) Annual
Meeting and American Association for Cancer Research (AACR) 2022
Annual Meeting, highlighting Genetron Health's patented One-Step™
Seq Method and core products including Onco PanScan™, for use in
full-cycle cancer management.
- Launched the Genetron Health Cancer
Early Screening Center, and the Genetron Health Future Science and
Technology Experience Hall in Wuxi, Jiangsu Province of East China.
The new facilities will further support the development of national
projects for early screening for comprehensive prevention &
control of liver cancer and the "rural revitalization - medical
help" project, as well as to promote the development of science
popularization.
- Launched Onco SonarTM, a 170-gene
pan-cancer solid tumor NGS liquid biopsy assay, which includes 106
genes of strong clinical significance and 64 genes that occur in
high frequency in main cancer populations. The assay enables
informed treatment decisions for advanced solid-tumor cancer
patients and identifies treatment options or suitable clinical
trials for patients before first-line therapy or amid disease
progression.
- Received CE mark for two new tests,
Human B Lymphocyte Minimal Residual Disease Testing Kit Seq-MRD®
and FusionScan Plus Kit for Human Multi-Genes.
- Continued to advance in-hospital
efforts with 62 hospital partners, of which 31 were IVD in-hospital
partners as of June 30, 2022.
- Launched COVID-19 testing services
in May as part of the local community's routine efforts to manage
the pandemic in Beijing.
Second Quarter 2022 Financial
Highlights
- Generated total revenue of RMB
137.7 million (US $20.6 million) in the second quarter of 2022,
representing a 1.9% decrease over the same period in 2021.
- LDT revenue was RMB 114.9 million
(US $17.1 million), representing a 31.8% increase over the same
period in 2021, including RMB 48.9 million (US $7.3 million) of
COVID-19 testing service revenue.
- IVD revenue was RMB 9.3 million (US
$1.4 million), representing a 78.8% decrease year-over-year.
- Development services revenue was
RMB 13.6 million (US $2.0 million), representing a 42.8% increase
over the same period in 2021.
Second Quarter 2022 Unaudited Financial
Results
Total revenue for the second quarter of 2022 decreased by 1.9%
to RMB 137.7 million (US $20.6 million) in the second quarter of
2022 from RMB 140.5 million in the same period of 2021.
Diagnosis and monitoring revenue decreased by
5.2% to RMB 124.2 million (US $18.5 million) in the second quarter
of 2022 from RMB 131.0 million in the same period of 2021,
primarily attributable to a decrease in revenue from the IVD
product sales.
- Revenue generated from the
provision of LDT services increased by 31.8% to RMB 114.9 million
(US $17.1 million) during the second quarter of 2022 from RMB 87.1
million in the same period of 2021. This increase was primarily
driven by the COVID-19 testing service revenue of RMB 48.9 million
(US $7.3 million), which was included in our second quarter sales
of LDT services and offset by decreases in diagnosis and monitoring
and early screening services. LDT diagnostic tests, excluding
COVID-19 testing, sold in the second quarter 2022 totaled
approximately 5,292 units, representing a decrease of 22.6%
compared to the number of LDT diagnostic tests sold in the same
period of 2021. The decrease was primarily driven by the COVID-19
pandemic situation in major Chinese cities.
- Revenue generated from the sale of
IVD products decreased by 78.8% to RMB 9.3 million (US $1.4
million) in the second quarter of 2022 from RMB 43.8 million in the
second quarter of 2021. The decrease was primarily driven by the
COVID-19 pandemic situation in major Chinese cities.
Revenue generated from development services
increased by 42.8% to RMB 13.6 million (US $2.0 million) in the
second quarter of 2022, from RMB 9.5 million in the same period of
2021. The increase was primarily driven by the increase in
biopharma services.
Gross profit decreased by 40.6% to RMB 56.1
million (US $8.4 million) in the second quarter of 2022 from RMB
94.5 million in the same period of 2021. Gross margin decreased to
40.7% for the second quarter of 2022, compared to 67.2% in the same
period of 2021, primarily driven by product mix shift and the low
gross margins of COVID-19 testing services resulting from
government pricing protocols.
Operating expenses increased by 16.2% to RMB
226.2 million (US $33.8 million) for the three months ended June
30, 2022, from RMB 194.6 million in the same period of 2021.
Selling expenses increased by 7.0% to RMB 94.7
million (US $14.1 million) in the second quarter of 2022 from RMB
88.5 million in the same period of 2021. Selling expenses as a
percentage of revenues increased to 68.7% in the second quarter of
2022 from 63.0% in the same period of 2021. The growing number of
salespeople primarily drove the increase.
Administrative expenses increased by 10.2% to
RMB 60.1 million (US $9.0 million) in the second quarter of 2022
from RMB 54.6 million in the same period of 2021. Administrative
expenses as a percentage of revenues increased to 43.7% in the
second quarter of 2022 from 38.8% in the second quarter of 2021.
The increase was mainly driven by increased administrative costs
associated with conducting COVID-19 testing.
Research and development expenses increased by
9.8% to RMB 61.6 million (US $9.2 million) in the second quarter of
2022 from RMB 56.2 million in the same period of 2021. Research and
development expenses as a percentage of revenues increased to 44.7%
in the second quarter of 2022 from 40.0% in the same period of
2021. The increases were driven by higher R&D headcount and
related expenses, including product development and clinical trial
activities.
As a result of the above, operating loss was RMB
170.1 million (US $25.4 million) for the three months ended June
30, 2022, compared to RMB 100.2 million for the three months ended
June 30, 2021.
Finance costs-net increased to RMB 66.1 million
(US $9.9 million) in the second quarter of 2022 from finance
income-net of RMB 8.0 million in the same period of 2021. The
increase was driven by the foreign currency exchange loss
due to the significant change in exchange rate between RMB and USD.
Loss for the period was RMB 236.2 million (US
$35.3 million) for the three months ended June 30, 2022, compared
to RMB 92.1 million for the three months ended June 30, 2021.
Non-IFRS loss for the period, defined as loss
for the period excluding share-based compensation expenses, was RMB
228.0 million (US $34.0 million) for the three months ended June
30, 2022, compared to RMB 79.6 million for the three months ended
June 30, 2021. Please refer to the section in this press release
titled "Non-IFRS Financial Measures" for details.
Basic loss per ordinary share for loss
attributable to owners of the Company was RMB 0.51 (US $0.08) for
the second quarter of 2022, compared with a basic loss per ordinary
share for loss attributable to owners of the Company of RMB 0.20
for the same period of 2021. Excluding share-based compensation
expenses, non-IFRS basic loss per ordinary share for loss
attributable to owners of the Company was RMB 0.49 (US $0.07) for
the second quarter of 2022, compared with non-IFRS basic loss per
ordinary share for loss attributable to owners of the Company of
RMB 0.17 for the same period of 2021. Diluted loss per ordinary
share for loss attributable to owners of the Company is equivalent
to basic loss per ordinary share for loss attributable to owners of
the Company. Each ADS represents five ordinary shares, par value
US$0.00002 per share. Please refer to the section in this press
release titled "Non-IFRS Financial Measures" for details.
Cash and cash equivalents and current financial
assets at fair value through profit or loss were RMB 472.7 million
(US $70.6 million) as of June 30, 2022.
Recent DevelopmentOn August 22,
2022, the Company announced that it received a preliminary
non-binding offer dated August 21, 2022, to acquire all the
outstanding ordinary shares, including those represented by the
American depositary shares of the Company (ADSs), for US $0.27 per
Ordinary Share or US $1.36 per ADS in cash. Since receiving the
proposal, the Company’s Board of Directors has formed a special
committee and retained Kroll, LLC as its independent financial
advisor and Davis Polk & Wardwell LLP as its independent legal
counsel to evaluate this offer and other potential strategic
alternatives the Company may pursue.
Exchange Rate Information All
translations made in the financial statements or elsewhere in this
press release made from RMB into United States dollars ("US$") are
solely for convenience and calculated at the rate of US $1.00 = RMB
6.6981, representing the exchange rate as of June 30, 2022, set
forth in the H.10 statistical release of the U.S. Federal Reserve
Board. No representation is made that the RMB amounts could have
been, or could be, converted, realized or settled into US$ at that
rate, or at any other rate, on June 30, 2022.
Non-IFRS Financial Measures The
Company uses non-IFRS loss and non-IFRS loss per share for loss
attributable to owners of the Company for the year/period, which
are non-IFRS financial measures, in evaluating its operating
results and for financial and operational decision-making purposes.
The Company believes that non-IFRS loss and non-IFRS loss per share
for loss attributable to owners of the Company help identify
underlying trends in the Company's business that could otherwise be
distorted by the effect of certain expenses that the Company
includes in its loss for the year/period. The Company believes that
non-IFRS loss and non-IFRS loss per share for loss attributable to
owners of the Company for the year/period provide useful
information about its results of operations, enhances the overall
understanding of its past performance and future prospects and
allows for greater visibility with respect to key metrics used by
its management in its financial and operational
decision-making.
Non-IFRS loss and non-IFRS loss per share for
loss attributable to owners of the Company for the year/period
should not be considered in isolation or construed as an
alternative to operating profit, loss for the year/period or any
other measure of performance or as an indicator of its operating
performance. Investors are encouraged to review non-IFRS loss and
non-IFRS loss per share for loss attributable to owners of the
Company for the year/period and the reconciliation to its most
directly comparable IFRS measures. Non-IFRS loss and non-IFRS loss
per share for loss attributable to owners of the Company for the
year/period presented here may not be comparable to similarly
titled measures presented by other companies. Other companies may
calculate similarly titled measures differently, limiting their
usefulness as comparative measures to the Company's data. The
Company encourages investors and others to review its financial
information in its entirety and not rely on a single financial
measure.
Non-IFRS loss and non-IFRS loss per share for
loss attributable to owners of the Company for the year/period
represent loss for the year/period excluding share-based
compensation expenses, fair value change of financial instruments
with preferred rights and other loss of financial instruments with
preferred rights (if applicable).
Please see the "Unaudited Non-IFRS Financial
Measures" included in this press release for a full reconciliation
of non-IFRS loss for the year/period to loss for the year/period
and non-IFRS loss per share for loss attributable to owners of the
Company for the year/period to loss per share for loss attributable
to owners of the Company for the year/period.
About Genetron Holdings
LimitedGenetron Holdings Limited ("Genetron Health" or the
"Company") (Nasdaq: GTH) is a leading precision oncology platform
company in China that specializes in cancer molecular profiling and
harnesses advanced technologies in molecular biology and data
science to transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement This
press release contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company's beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as "may", "will," "expect," "anticipate," "target," “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations ContactUS:
Philip Trip TaylorPrincipal | Gilmartin
Groupir@genetronhealth.com
Media Relations ContactYuxin ShouGenetron
Healthyuxin.shou@genetronhealth.com
Edmond LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408genetron.pr@icrinc.com
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
LOSS
| |
For the three months ended |
|
For the six months ended |
| |
June 30, 2021 |
|
June 30, 2022 |
|
June 30, 2021 |
|
June 30, 2022 |
| |
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
Revenue |
140,485 |
|
|
137,749 |
|
|
20,565 |
|
|
232,546 |
|
|
248,070 |
|
|
37,036 |
|
| Cost of revenue |
(46,021 |
) |
|
(81,656 |
) |
|
(12,191 |
) |
|
(83,533 |
) |
|
(130,507 |
) |
|
(19,484 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross
profit |
94,464 |
|
|
56,093 |
|
|
8,374 |
|
|
149,013 |
|
|
117,563 |
|
|
17,552 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selling expenses |
(88,516 |
) |
|
(94,695 |
) |
|
(14,137 |
) |
|
(148,187 |
) |
|
(185,539 |
) |
|
(27,700 |
) |
| Administrative expenses |
(54,577 |
) |
|
(60,136 |
) |
|
(8,978 |
) |
|
(99,180 |
) |
|
(110,378 |
) |
|
(16,479 |
) |
| Research and development
expenses |
(56,162 |
) |
|
(61,641 |
) |
|
(9,203 |
) |
|
(106,136 |
) |
|
(141,200 |
) |
|
(21,081 |
) |
| Net impairment losses on
financial and contract assets |
(3,474 |
) |
|
(8,749 |
) |
|
(1,306 |
) |
|
(13,304 |
) |
|
(21,848 |
) |
|
(3,262 |
) |
| Other income and
gains/(losses) - net |
8,081 |
|
|
(989 |
) |
|
(148 |
) |
|
8,611 |
|
|
(8,603 |
) |
|
(1,284 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating expenses |
(194,648 |
) |
|
(226,210 |
) |
|
(33,772 |
) |
|
(358,196 |
) |
|
(467,568 |
) |
|
(69,806 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating
loss |
(100,184 |
) |
|
(170,117 |
) |
|
(25,398 |
) |
|
(209,183 |
) |
|
(350,005 |
) |
|
(52,254 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finance income |
9,447 |
|
|
541 |
|
|
81 |
|
|
5,179 |
|
|
1,412 |
|
|
211 |
|
| Finance costs |
(1,409 |
) |
|
(66,602 |
) |
|
(9,943 |
) |
|
(3,180 |
) |
|
(62,479 |
) |
|
(9,328 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finance income/(costs) -
net |
8,038 |
|
|
(66,061 |
) |
|
(9,862 |
) |
|
1,999 |
|
|
(61,067 |
) |
|
(9,117 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss before income
tax |
(92,146 |
) |
|
(236,178 |
) |
|
(35,260 |
) |
|
(207,184 |
) |
|
(411,072 |
) |
|
(61,371 |
) |
| Income tax expense |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss for the
period |
(92,146 |
) |
|
(236,178 |
) |
|
(35,260 |
) |
|
(207,184 |
) |
|
(411,072 |
) |
|
(61,371 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss attributable
to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Owners of the Company |
(91,820 |
) |
|
(235,215 |
) |
|
(35,116 |
) |
|
(204,574 |
) |
|
(409,587 |
) |
|
(61,149 |
) |
| Non-controlling interests |
(326 |
) |
|
(963 |
) |
|
(144 |
) |
|
(2,610 |
) |
|
(1,485 |
) |
|
(222 |
) |
| |
(92,146 |
) |
|
(236,178 |
) |
|
(35,260 |
) |
|
(207,184 |
) |
|
(411,072 |
) |
|
(61,371 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss per share for
loss attributable to owners of the Company |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
RMB |
|
|
USD |
|
| -Basic and diluted |
(0.20 |
) |
|
(0.51 |
) |
|
(0.08 |
) |
|
(0.45 |
) |
|
(0.88 |
) |
|
(0.13 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss per ADS for loss
attributable to owners of the Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -Basic and diluted |
(1.00 |
) |
|
(2.54 |
) |
|
(0.38 |
) |
|
(2.23 |
) |
|
(4.42 |
) |
|
(0.66 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares used in loss
per share computation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -Basic and diluted |
459,903,803 |
|
|
463,590,375 |
|
|
463,590,375 |
|
|
458,999,227 |
|
|
463,231,584 |
|
|
463,231,584 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADS used in loss per
ADS computation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -Basic and diluted |
91,980,761 |
|
|
92,718,075 |
|
|
92,718,075 |
|
|
91,799,845 |
|
|
92,646,316 |
|
|
92,646,316 |
|
GENETRON HOLDINGS LIMITED
UNAUDITED NON-IFRS FINANCIAL MEASURE
| |
For the three months ended |
|
For the six months ended |
| |
June 30, 2021 |
|
June 30, 2022 |
|
June 30, 2021 |
|
|
June 30, 2022 |
| |
|
|
|
|
|
|
|
|
|
|
|
| |
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss for the
period |
(92,146 |
) |
|
(236,178 |
) |
|
(35,260 |
) |
|
(207,184 |
) |
|
(411,072 |
) |
|
(61,371 |
) |
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share-based compensation |
12,504 |
|
|
8,144 |
|
|
1,216 |
|
|
21,754 |
|
|
19,488 |
|
|
2,909 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-IFRS
Loss |
(79,642 |
) |
|
(228,034 |
) |
|
(34,044 |
) |
|
(185,430 |
) |
|
(391,584 |
) |
|
(58,462 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Attributable
to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Owners of the Company |
(79,316 |
) |
|
(227,071 |
) |
|
(33,900 |
) |
|
(182,820 |
) |
|
(390,099 |
) |
|
(58,240 |
) |
| Non-controlling interests |
(326 |
) |
|
(963 |
) |
|
(144 |
) |
|
(2,610 |
) |
|
(1,485 |
) |
|
(222 |
) |
| |
(79,642 |
) |
|
(228,034 |
) |
|
(34,044 |
) |
|
(185,430 |
) |
|
(391,584 |
) |
|
(58,462 |
) |
| Non-IFRS loss per
share for loss attributable to owners of the
Company |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
RMB |
|
|
USD |
|
| -Basic and diluted |
(0.17 |
) |
|
(0.49 |
) |
|
(0.07 |
) |
|
(0.40 |
) |
|
(0.84 |
) |
|
(0.13 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-IFRS loss per
ADS(5 ordinary shares equal to 1 ADS) for loss
attributable to owners of the Company |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -Basic and diluted |
(0.86 |
) |
|
(2.45 |
) |
|
(0.37 |
) |
|
(1.99 |
) |
|
(4.21 |
) |
|
(0.63 |
) |
| |
|
|
|
|
|
| Shares
used in non-IFRS loss per share computation: |
|
|
|
|
|
| -Basic and diluted |
459,903,803 |
|
|
463,590,375 |
|
|
463,590,375 |
|
|
458,999,227 |
|
|
463,231,584 |
|
|
463,231,584 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADS used in non-IFRS
loss per ADS computation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| -Basic and diluted |
91,980,761 |
|
|
92,718,075 |
|
|
92,718,075 |
|
|
91,799,845 |
|
|
92,646,316 |
|
|
92,646,316 |
|
GENETRON HOLDINGS LIMITEDUNAUDITED
REVENUE AND SEGMENT INFORMATION
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Diagnosis andmonitoring |
|
Diagnosis andmonitoring |
|
Developmentservices |
|
Total |
| |
- provision ofLDT services |
|
- sale of IVDproducts |
|
|
|
|
| |
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
| |
|
|
|
|
|
|
|
| Three months ended
June 30, 2021 |
|
|
|
|
|
|
|
| Revenue |
87,138 |
|
43,827 |
|
9,520 |
|
140,485 |
| Segment
profit |
61,890 |
|
31,312 |
|
1,262 |
|
94,464 |
| |
|
|
|
|
|
|
|
| Three months ended
June 30, 2022 |
|
|
|
|
|
|
|
| Revenue |
114,872 |
|
9,283 |
|
13,594 |
|
137,749 |
| Segment
profit |
48,236 |
|
4,681 |
|
3,176 |
|
56,093 |
| |
|
|
|
|
|
|
|
| Six months ended June
30, 2021 |
|
|
|
|
|
|
|
| Revenue |
158,966 |
|
59,093 |
|
14,487 |
|
232,546 |
| Segment
profit |
110,701 |
|
36,534 |
|
1,778 |
|
149,013 |
| |
|
|
|
|
|
|
|
| Six months ended June
30, 2022 |
|
|
|
|
|
|
|
| Revenue |
196,383 |
|
27,307 |
|
24,380 |
|
248,070 |
| Segment
profit |
100,287 |
|
13,615 |
|
3,661 |
|
117,563 |
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS
|
|
|
As of December 31, 2021 |
|
As of June 30, 2022 |
|
|
|
RMB’000 |
|
RMB’000 |
|
US$’000 |
| ASSETS |
|
|
|
|
|
|
| Non-current assets |
|
|
|
|
|
|
| Property, plant and equipment |
|
110,285 |
|
155,414 |
|
23,203 |
| Right-of-use assets |
|
52,074 |
|
49,634 |
|
7,410 |
| Intangible assets |
|
20,695 |
|
27,892 |
|
4,164 |
| Financial assets at fair value through profit or loss |
|
49,780 |
|
49,201 |
|
7,346 |
| Prepayments |
|
37,610 |
|
31,460 |
|
4,697 |
| |
|
|
|
|
|
|
| Total non-current assets |
|
270,444 |
|
313,601 |
|
46,820 |
| |
|
|
|
|
|
|
| Current assets |
|
|
|
|
|
|
| Inventories |
|
35,603 |
|
55,023 |
|
8,215 |
| Contract assets |
|
7,775 |
|
9,888 |
|
1,476 |
| Other current assets |
|
30,705 |
|
29,886 |
|
4,462 |
| Trade receivables |
|
282,113 |
|
309,056 |
|
46,141 |
| Other receivables and prepayments |
|
97,895 |
|
113,020 |
|
16,873 |
| Amounts due from related parties |
|
597 |
|
212 |
|
32 |
| Financial assets at fair value through profit or loss |
|
151,443 |
|
145,128 |
|
21,667 |
| Derivative financial instruments |
|
2,002 |
|
- |
|
- |
| Cash and cash equivalents |
|
639,042 |
|
327,551 |
|
48,902 |
| |
|
|
|
|
|
|
| Total current assets |
|
1,247,175 |
|
989,764 |
|
147,768 |
| |
|
|
|
|
|
|
| Total assets |
|
1,517,619 |
|
1,303,365 |
|
194,588 |
GENETRON HOLDINGS LIMITED
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
（CONTINUED）
|
|
|
As of December 31, 2021 |
|
As of June 30, 2022 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
US$’000 |
|
| |
|
|
|
|
|
|
|
|
|
| LIABILITIES |
|
|
|
|
|
|
|
|
|
| Non-current liabilities |
|
|
|
|
|
|
|
|
|
| Borrowings |
|
- |
|
|
19,194 |
|
|
2,866 |
|
| Lease liabilities |
|
33,865 |
|
|
29,967 |
|
|
4,474 |
|
| Other non-current liabilities |
|
8,612 |
|
|
9,181 |
|
|
1,371 |
|
| Total non-current liabilities |
|
42,477 |
|
|
58,342 |
|
|
8,711 |
|
| |
|
|
|
|
|
|
|
|
|
| Current liabilities |
|
|
|
|
|
|
|
|
|
| Trade payables |
|
55,767 |
|
|
53,687 |
|
|
8,015 |
|
| Contract liabilities |
|
11,962 |
|
|
25,996 |
|
|
3,881 |
|
| Other payables and accruals |
|
157,232 |
|
|
157,172 |
|
|
23,465 |
|
| Amounts due to related parties |
|
3 |
|
|
1,307 |
|
|
195 |
|
| Borrowings |
|
19,554 |
|
|
89,958 |
|
|
13,430 |
|
| Lease liabilities |
|
20,572 |
|
|
21,978 |
|
|
3,281 |
|
| |
|
|
|
|
|
|
|
|
|
| Total current liabilities |
|
265,090 |
|
|
350,098 |
|
|
52,267 |
|
| |
|
|
|
|
|
|
|
|
|
| Total liabilities |
|
307,567 |
|
|
408,440 |
|
|
60,978 |
|
| |
|
|
|
|
|
|
|
|
|
| Net assets |
|
1,210,052 |
|
|
894,925 |
|
|
133,610 |
|
| |
|
|
|
|
|
|
|
|
|
| SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
| Equity attributable to owners of the
Company |
|
|
|
|
|
|
|
|
|
| Share capital |
|
61 |
|
|
61 |
|
|
9 |
|
| Share premium |
|
6,711,234 |
|
|
6,717,362 |
|
|
1,002,876 |
|
| Other reserves |
|
(69,091 |
) |
|
20,726 |
|
|
3,095 |
|
| Accumulated losses |
|
(5,436,613 |
) |
|
(5,846,200 |
) |
|
(872,814 |
) |
| |
|
1,205,591 |
|
|
891,949 |
|
|
133,166 |
|
| Non-controlling interests |
|
4,461 |
|
|
2,976 |
|
|
444 |
|
| |
|
|
|
|
|
|
|
|
|
| Total shareholders’ equity |
|
1,210,052 |
|
|
894,925 |
|
|
133,610 |
|
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024
